## [AI/ML-Based SaMD 2026: FDA AI Guidance, EU AI Act, Total Product Lifecycle (TPLC) & Algorithm Manufacturing](/blog/aiml-based-samd-2026-fda-ai-guidance-eu-ai-act-total-product-lifecycle-tplc-algorithm-manufacturing) March 26, 2026 ![AI/ML-Based SaMD 2026: FDA AI Guidance, EU AI Act, Total Product Lifecycle (TPLC) & Algorithm Manufacturing]() 6 min read - [Medical Devices](/blog-main-categories/medical-devices) - [Digital Health](/blog-main-categories/digital-health) AI-enabled software is moving from “assistive” functionality to systems that meaningfully shape clinical decisions and operational workflows. That evolution is accelerating innovation, but it is also tightening expectations around governance, transparency, and lifecycle control. In 2026, the most consequential shift for many developers is not *whether* regulators will accept AI/ML, but *how* they expect manufacturers to manage continuous change without compromising safety and effectiveness. For teams building SaMD AI capabilities, the Regulatory conversation is increasingly lifecycle-centric. The question regulators are asking is straightforward. If the model evolves, how do you preserve clinical validity, control risk, and document change in a way that remains auditable? This blog unpacks the practical implications of this shift, focusing on Total Product Lifecycle (TPLC) thinking and “algorithm manufacturing,” where ongoing model updates are treated with the discipline of a production process rather than a one-time development event. ### The New Baseline: Lifecycle Governance for Learning Systems The biggest misconception in AI/ML in SaMD is that an approved model is “done.” In reality, AI-enabled SaMD behaves more like a living system. Performance depends on data quality, clinical context, user interaction patterns, and deployment conditions. Over time, drift, dataset shift, and workflow changes can create silent performance degradation, especially in high-variability environments like imaging, triage, and monitoring. This is why regulators increasingly evaluate your operating model, not just your premarket package. A credible plan shows how you will detect issues early, constrain risk, and manage updates with rigor. For a medical device, that means engineering practices must be tightly integrated with quality systems, post-market monitoring, and change control. ### What 2026 means for FDA AI ML: PCCPs and TPLC as a Practical Playbook The FDA’s direction is clear: safe innovation in AI depends on predictable, pre-defined update governance. In practice, this is where FDA AI regulation becomes operational through structured plans that define what can change, how changes will be validated, and what will be monitored post-deployment. A pivotal mechanism for that is the Predetermined Change Control Plan (PCCP). The [FDA’s final guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence?) on PCCPs provides a concrete framework for pre-authorizing categories of model updates without requiring a new submission for every covered change, provided the plan’s validation and monitoring commitments are met. This approach aligns with the FDA’s broader Total Product Lifecycle expectations for FDA SaMD, where the “product” is not just the release artifact but the system of controls that sustains safety across versions. For teams interpreting SaMD and FDA guidance, the practical takeaway is that governance is becoming part of the evidence. ### The EU lens: MDR meets the EU AI Act In Europe, AI-enabled SaMD sits at the intersection of medical device regulation and horizontal AI governance. MDR still anchors clinical performance, safety, and post-market obligations. Still, the EU AI Act introduces additional expectations related to risk management, transparency, accountability, and oversight for high-risk AI systems, especially where outputs can materially influence clinical decisions. The official legal text of the [EU AI Act](https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng?) clarifies scope, obligations, and governance requirements at the EU level. For developers, the strategic move is integration, not duplication. If you build a parallel “AI compliance” track separate from your QMS and clinical governance, you create the risk of inconsistency. The more scalable approach is to map AI Act expectations onto existing MDR-aligned lifecycle controls: risk management, documentation tied to clinical claims, and post-market monitoring that includes drift, bias signals, and usability-related hazards. ### IMDRF and “good practice” as the global common language Global convergence is still imperfect, but it is accelerating around common principles. IMDRF work has been influential in shaping shared expectations for AI-enabled medical devices, particularly on good practices that should apply across the lifecycle. The [IMDRF SaMD](https://www.imdrf.org/sites/default/files/2025-02/IMDRF_AIML%20WG_GMLP_N88%20Final.pdf?) ecosystem increasingly treats “good machine learning practice” as a baseline for safe development, validation, and maintenance. At a practical level, this helps manufacturers translate strategy across regions, even if dossier formats differ, the underlying expectations about data governance, evaluation rigor, and monitoring discipline are becoming more consistent. ### Algorithm Manufacturing: Turning Model Updates into a Controlled Production Process If you want a single mental model for 2026, it is AI-enabled SaMD that requires “algorithm manufacturing.” That means treating model updates like controlled production, with standardized inputs, methods, acceptance criteria, and release decisions that are auditable. A strong approach usually includes: - Clearly defined “change types” (data refresh, threshold tuning, model architecture changes) and what evidence each requires - A locked evaluation protocol that can be run repeatedly across versions - Monitoring signals that meaningfully reflect clinical performance (not just technical metrics) - Governance that links changes to intended use, risk controls, and labeling claims This is where artificial intelligence and machine learning in software-as-a-medical-device shift from model sophistication to lifecycle discipline. The winners in the next cycle will be teams that can innovate *and* demonstrate control. ### Where Value Concentrates: Real-world Applications that Drive Scrutiny The highest scrutiny often occurs when AI outputs can directly shift care decisions. Applications of AI/ML in Software as a Medical Device commonly include detection, triage, risk prediction, and workflow optimization areas where evidence quality and drift monitoring matter as much as model accuracy. A particularly important category is Clinical Decision Support Systems, where AI outputs may influence diagnosis or treatment choices. Here, regulators tend to probe three questions, i.e., What clinical decision is affected? What is the consequence of an error? And how is the human user expected to interpret and act on outputs under real-world conditions? This scrutiny is also tied to macro growth. As the software-as-a-medical-device market expands, regulators are increasingly focused on scalable governance models that can keep pace with adoption, iterative releases, and multi-market deployment. ### Closing: strategy as a lifecycle system, not a launch event AI-enabled SaMD regulation in 2026 is converging on a core principle. Continuous learning demands continuous control. Whether you are aligning with SaMD regulations in the US, Europe, or globally, regulators are moving toward the same outcome confidence that performance holds over time and that change is managed responsibly. In practice, teams that operationalize TPLC thinking connecting evidence durability, change governance, and real-world monitoring tend to align more consistently with expectations outlined in [Comprehensive Guide to Software as a Medical Device (SaMD) Compliance & Global Registration](/blog/comprehensive-guide-to-software-as-a-medical-device-samd-compliance-global-registration) and the lifecycle operating requirements addressed in Software as a Medical Device (SaMD) Regulatory Compliance. [Contact Freyr Solutions](https://www.freyrsolutions.com/medical-devices/software-as-a-medical-device-samd-regulatory-compliance) to discuss your SaMD Regulatory strategy and discover how Freyr can streamline your global registrations. ## FAQs #### [What is different about regulating AI/ML in SaMD compared to traditional SaMD?](#collapseOne) AI/ML-enabled SaMD behaves more like a living system than a static product. Performance can shift due to dataset drift, workflow changes, or updates to model parameters. Regulators, therefore, emphasize lifecycle governance, which involves validating, monitoring, and controlling change over time rather than evaluating only a one-time submission package. #### [How does the FDA AI regulation address ongoing model updates?](#collapseTwo) FDA’s approach increasingly supports controlled iteration through mechanisms like Predetermined Change Control Plans (PCCPs), where manufacturers define what can change, how updates will be validated, and what monitoring will be in place. This makes lifecycle control part of the evidence, aligning well with Total Product Lifecycle thinking for FDA AI/ML and FDA SaMD oversight. #### [How does the EU AI Act affect AI medical devices regulated under MDR?](#collapseThree) The EU AI Act introduces additional governance expectations for high-risk AI systems, especially transparency, accountability, risk management, and human oversight. For AI-enabled medical devices, the most practical approach is integration: mapping AI Act controls onto existing MDR-aligned lifecycle processes rather than creating a separate compliance track. #### [What are the most common Applications of AI/ML in Software as a Medical Device today?](#collapseFour) Common applications include imaging analysis, triage and prioritization, predictive risk scoring, therapy optimization, and monitoring deterioration. Clinical Decision Support Systems are especially scrutinized because they can influence diagnosis or treatment decisions; regulators often focus on clinical impact, error consequences, interpretability, and real-world performance monitoring. #### [How can Freyr support organizations developing SaMD AI products in 2026?](#collapseFIve) Freyr helps organizations align AI/ML-enabled SaMD development with evolving global expectations by supporting lifecycle-based Regulatory planning, evidence strategy, change-control governance, and post-market performance monitoring. Freyr’s Regulatory intelligence capabilities along with platforms like Freya Fusion can also help teams stay current on fast-moving SaMD regulations, interpret emerging guidance, and assess the impact of regulatory updates across key markets.